Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2021, Review
2021

Non-anticoagulant and other properties of low molecular weight heparins: 615.035.1:616-005

Review
Published 2021-11-30
Eugene Roitman
Pirogov Russian National Research Medical University, Health Ministry of Russian Federation; 1 Ostrovityanova Str., Moscow 117997, Russia; Research Center of Neurology; 80 Volokolamskoe Shosse, Moscow 125367, Russia
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации; Россия, 117997 Москва, ул. Островитянова, 1; ФГБНУ «Научный центр неврологии»; Россия, 125367 Москва, Волоколамское шоссе, 80
Valery Pechennikov
Sechenov First Moscow State Medical University, Health Ministry of Russian Federation; 2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991, Russia
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); Россия, 119991 Москва, ул. Большая Пироговская, 2, стр. 4

Keywords

low molecular weight heparin(s)
antioxidant effect
anti-inflammatory effect
antitumor activity
anti-angiogenic activity
  Full Text

Abstract

Summury. Low molecular weight heparins (LMWHs) make one pharmacological group due to their antithrombotic action, but each of their international nonproprietary names provides additionally its own spectrum of pleiotropic (non-antithrombotic) actions with a specific profile for clinical efficacy. Due to the differences in the structure of these medications the results obtained with one LMWH should not be transferred to another. However, differences between LMWHs do not make one better or worse than the other. On the contrary, it allows you to choose if not optimal then the most suitable LMWH for the patient taking into account a number of influencing factors as well.

References:

  1. Haoa C., Sunb M., Wang H. et al. Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci. 2019;163:21– DOI: 10.1016/bs.pmbts.2019.02.003. 

  2. Yan Y., Ji Y., Su N. et al. Non‐anticoagulant effects of low mole‐ cular weight heparins in inflammatory disorders: a review. Car- bohydr Polym. 2017;160:71–81. DOI: 10.1016/j.carbpol.2016.12.037. 

  3. Simonneau G., Laporte S., Mismetti P. et al.; FX140 Study Inves‐ A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost. 2006;4(8):1693–700. DOI: 10.1111/j.1538–7836.2006.02083.x. 

  4. Fareed J, Walenga J.M., Hoppensteadt D. et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci. 1989;556:333–53. DOI: 10.1111/j.1749–6632.1989. x. 

  5. Connors J.M., Levy J.H. Thromboinflammation and the hyperco‐ agulability of COVID‐ J Thromb Haemost. 2020;18(7):1559–61. DOI: 10.1111/jth.14849.
  6. RoitmanE.V., Bulanov A.Yu., PechennikovV.M.Low molecular weight heparins dosing and anti‐factor Xa activity in patients with novel coronavirus infection COVID‐19. Tromboz, gemo- staz i reologiya. 2020;(4):57–67. (In Russ.). DOI: 10.25555/ THR.2020.4.0946.
  7. Zabolotskikh I.B., Kirov M. Yu., Lebedinskii K.M. et al. Anesthesia and intensive care for patients with COVID‐19. Russian Federa‐ tion of anesthesiologists and reanimatologists guidelines. Vest- nik intensivnoj terapii imeni A.I. Saltanova. 2021;(S1):9–143. DOI: 10.21320/1818–474X‐2021‐S1–9–143.

  8. Mousa S.A., PetersenL.J.Anti‐cancer properties of low‐ molecular‐weight heparin: preclinical evidence. Thromb Hae- most. 2009;102(2):258–67. DOI: 10.1160/TH08–12–0832.

  9. Brown R.A., Allegra L., Matera M.G. et al. Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther. 2006;19(6):419–24. DOI: 10.1016/j.pupt.2006.04.004.
  10. Shastri M.D., Peterson G.M., Stewart N. et al. Nonanticoagulant derivatives of heparin for the management of asthma: distant dream or close reality? Expert Opin Investig Drugs. 2014;23(3):357– DOI: 10.1517/13543784.2014.866092.
  11. Lean Q.Y., Gueven N., Eri R.D. et al. Heparins in ulcerative colitis: 
proposed mechanisms of action and potential reasons for inconsis‐ tent clinical outcomes. Expert Rev Clin Pharmacol. 2015;8(6):795– 811. DOI: 10.1586/17512433.2015.1082425. 

  12. Iraji F., Asilian A., Saeidi A. et al. Comparison of therapeutic effect of low‐dose low‐molecular weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical Adv Biomed Res. 2013;2:76. DOI: 10.4103/2277–9175.115798. 

  13. Walenga J.M., Jackson C.M., Kessler C.M. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Semin Thromb Hemost. 2011;37(3):322–27. DOI: 10.1055/ s‐0031–12745151. 

  14. Yalniz M., Demirel U., Orhan C. et al. Nadroparin sodium acti‐ vates Nrf2/HO‐1 pathway in acetic acid‐induced colitis in rats. Inflammation. 2012;35(3):1213–21. DOI: 10.1007/s10753–012–9431‐ 

  15. Lee J.H., Lee H., Joung Y.K. et al. The use of low molecular weight heparin‐pluronic nanogels to impede liver fibrosis by inhibition the TGF‐β/Smad signaling pathway. Biomaterials. 2011;32(5):1438– DOI: 10.1016/j.biomaterials.2010.10.023. 

  16. Zhang N., Lou W., Ji F. et al. Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms. J Cancer Res Clin Oncol. 2016;142(8):1807–16. DOI: 10.1007/s00432– 016–2131–6. 

  17. Dogan O.T., Polat Z.A., Karahan O. et al. Antiangiogenic activi‐ ties of bemiparin sodium, enoxaparin sodium, nadroparin cal‐ cium and tinzaparin sodium. Thrombs Res. 2011;128(4): e29–32. DOI: 10.1016/j.thromres.2011.05.005. 

  18. Copeland R., Balasubramaniam A., Tiwari V. et al. Using a 3‐O‐sul‐ fated heparin octasaccharide to inhibit the entry of herpes sim‐ plex virus type 1. Biochemistry. 2008;47(21):5774–83. DOI: 10.1021/ 

  19. Guo Y., Wang Z., Dong L. et al. Ability of low‐molecular‐weight heparin to alleviate proteinuria by inhibiting respiratory syncy‐ tial virus infection. Nephrology (Carlton). 2008;13(7):545–53. DOI: 1111/j.1440–1797.2008.01012.x.
  20. Sadowski R., Gadzała‐Kopciuch R., Kowalkowski T. et al. Char‐ acterization of low‐molecular‐weight heparins by strong anion‐ exchange chromatography. J AOAC Int. 2017;100(6):1706–17. DOI: 10.5740/jaoacint.17–0217.
  21. Arnold K.M., Capuzzi S.J., Xu Y. et al. Modernization of enoxapa‐ rin molecular weight determination using homogeneous stan‐ Pharmaceuticals. 2017;10(3);66. DOI: 10.3390/ph10030066.
  22. Adiguzel C., Jeske W., Hoppensteadt D. et al. Structural and functional characterization of low‐molecular‐weight hepa‐ rins: impact on the development of guidelines for generic products. Clin Appl Thromb Hemost. 2009;15(2):137–44. DOI: 10.1177/1076029609332727.
  23. Jeske W., Walenga J., Hoppensteadt D. et al. Differentiating low molecular weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low‐molecular‐weight heparins. Semin Thromb Hemost. 2008;34(1):74–85. DOI: 10.1055/s‐2008–1066026.
  24. Hirsh J. Low Molecular Weight Heparins. 4th ed. Hamilton, Canada: Decker, 2007.
  25. Linhardt R.J., Loganathan D., al‐Hakim A. et al. Oligosaccharide mapping of low molecular weight heparins: structure and acti‐ vity differences. J Med Chem. 1990;33(6):1639–45. DOI: 10.1021/ jm00168a017.
  26. van der Wall S.J., Klok F.A., den Exter P.L. et al. Continuation of low‐molecular‐weight heparin treatment for cancer‐related venous thromboembolism: a prospective cohort study in daily clinical practice. J Thromb Haemost. 2017;15(1):74–9. DOI: 10.1111/ jth.13563.